论文部分内容阅读
目的探讨不同剂量阿托伐他汀早期治疗急性冠状动脉综合征(ACS)患者的效果。方法将北流市人民医院2012年12月至2014年11月收治的92例ACS患者随机分为两组,两组在常规治疗基础上加用阿托伐他汀,对照组剂量20 mg/d,观察组剂量为40 mg/d,1次/d,以连续用药8周为1个疗程。观察两组患者治疗前后血脂指标及C-反应蛋白(CRP)水平改善情况,记录随访6个月患者心血管事件发生情况。结果两组患者经治疗后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前均明显下降(P<0.05),其中观察组患者TC、LDL-C水平较对照组患者下降更为明显(P<0.05)。两组患者经治疗后CRP水平均较治疗前明显下降(P<0.05),观察组患者较对照组下降更为明显(P<0.05)。观察组6个月内心血管事件发生率为8.51%(4/47),明显低于对照组(26.67%,12/45),差异有统计学意义(P<0.05)。结论早期应用40 mg/d阿托伐他汀治疗,降脂及抑制炎症因子效果更明显,有助于减少心脏血管事件发生,而且安全性高。
Objective To investigate the effect of different doses of atorvastatin on patients with acute coronary syndrome (ACS). Methods 92 patients with ACS who were treated in Beiliu Municipal People’s Hospital from December 2012 to November 2014 were randomly divided into two groups. Atorvastatin was added to the two groups on the basis of conventional treatment, while the control group was given 20 mg / d, Observation group dose of 40 mg / d, 1 / d, continuous treatment for 8 weeks for a course of treatment. The changes of blood lipid and C-reactive protein (CRP) levels in both groups before and after treatment were observed. The incidence of cardiovascular events was recorded 6 months after follow-up. Results The levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were significantly decreased in both groups after treatment (P <0.05) The level of C was significantly lower than that of the control group (P <0.05). After treatment, CRP levels in both groups were significantly lower than those before treatment (P <0.05), and the patients in observation group were more obviously decreased than those in control group (P <0.05). The incidence of cardiovascular events within 6 months in the observation group was 8.51% (4/47), which was significantly lower than that in the control group (26.67%, 12/45). The difference was statistically significant (P <0.05). Conclusion At the early application of 40 mg / d of atorvastatin, lipid-lowering and anti-inflammatory cytokines are more effective in reducing cardiovascular events and are safe.